AC Immune (NASDAQ: ACIU) triggers $12M Takeda milestone with final ABATE cohort
Rhea-AI Filing Summary
AC Immune SA reported that it has dosed the first patients in Cohort AD4, the final planned cohort in its ongoing Phase 1b/2 ABATE trial of ACI-24, an anti-Abeta active immunotherapy for Alzheimer’s disease. Reaching this trial milestone triggers a $12 million payment from partner Takeda under their exclusive, worldwide option and license agreement for active immunotherapies targeting toxic amyloid beta.
The ABATE trial is evaluating ACI-24 in people with prodromal Alzheimer’s disease and adults with Down syndrome. Earlier cohorts AD1–AD3 enrolled 74 patients at escalating doses, with 12‑month data readouts expected later in Q2 2026. AD4 will initially enroll 36 patients treated for 12 months plus 6 months of follow-up, and may be expanded to about 112 subjects, substantially enlarging the safety and biomarker data set for ACI-24.
AC Immune highlights that ACI-24 has so far been generally safe and well tolerated, with anti-Abeta antibody responses observed at all tested doses and no safety concerns raised by multiple data safety monitoring board reviews. Under the Takeda agreement, AC Immune previously received $100 million upfront and remains eligible for an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1 billion, plus tiered double-digit royalties on any worldwide net sales.
Positive
- None.
Negative
- None.
Insights
AC Immune advances its lead Alzheimer’s program and unlocks a $12M milestone.
AC Immune has initiated Cohort AD4, the final planned cohort in the Phase 1b/2 ABATE trial of ACI-24 for prodromal Alzheimer’s disease and adults with Down syndrome. This step reflects continued progression of the program within an established trial design.
Dosing in AD4 triggers a $12 million milestone from Takeda under an exclusive option and license agreement covering active immunotherapies targeting toxic amyloid beta. This represents non-dilutive funding tied directly to clinical advancement and comes on top of a prior $100 million upfront payment and up to approximately $2.1 billion in additional potential milestones plus tiered double-digit royalties.
Data from earlier cohorts AD1–AD3, which enrolled 74 patients at escalating doses, have so far shown ACI-24 to be generally safe and well tolerated with anti-Abeta antibody responses at all tested doses, and multiple data safety monitoring board reviews have raised no safety concerns. Twelve‑month data readouts from these cohorts are expected in Q2 2026, while AD4 initially includes 36 patients with the possibility of expanding to about 112 subjects, which would materially enlarge the safety and biomarker data set if executed as described.
Key Figures
Key Terms
Phase 1b/2 medical
prodromal AD medical
immunogenicity medical
Data safety monitoring board (DSMB) medical
option and license agreement financial
tiered double-digit royalties financial
FAQ
What did AC Immune (ACIU) announce regarding the ABATE trial?
How much milestone revenue will AC Immune (ACIU) receive from Takeda?
What is ACI-24 and what does current data show for AC Immune (ACIU)?
How large is the ABATE trial for AC Immune’s (ACIU) ACI-24 program?
What is the financial potential of AC Immune’s (ACIU) agreement with Takeda?
When are key data readouts expected from AC Immune’s (ACIU) ABATE trial?
AI-generated analysis. How Rhea-AI works. Not financial advice.
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 6-K
REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16
UNDER THE SECURITIES EXCHANGE ACT OF 1934
For the month of April 2026
Commission file number: 001-37891
AC IMMUNE SA
(Exact Name of Registrant as Specified in Its Charter)
EPFL Innovation Park
Building B
1015 Lausanne, Switzerland
(Address of Principal Executive Offices)
Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
| Form 20-F | ☒ | Form 40-F | ☐ |
On April 30, 2026, AC Immune SA issued a press release announcing that it initiated the final cohort in the ongoing Phase 1b/2 ABATE trial of anti-Abeta active immunotherapy to treat Alzheimer’s disease. A copy of the press release is attached as Exhibit 99.1 to this Report on Form 6-K.
EXHIBIT INDEX
| Exhibit Number |
Description | |
| 99.1 | Press Release dated April 30, 2026 |
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.
| AC IMMUNE SA | ||
| By: | /s/ Andrea Pfeifer | |
| Name: Andrea Pfeifer | ||
| Title: Chief Executive Officer | ||
| By: | /s/ Christopher Roberts | |
| Name: Christopher Roberts | ||
| Title: Chief Financial Officer | ||
Date: April 30, 2026
|
||
Exhibit 99.1
 |
PRESS RELEASE |
AC Immune Initiates Final Cohort in Ongoing Phase
1b/2 ABATE
Trial of Anti-Abeta Active Immunotherapy to Treat Alzheimer's Disease
| · | Treatment of first patient in Cohort AD4 in ABATE trial triggers $12 million milestone payment |
| · | Allows evaluation of potential for precision prevention of neurodegenerative diseases |
| · | Data from ABATE Cohorts AD1, AD2 and AD3 after 12 months treatment expected Q2 2026 |
Lausanne, Switzerland, April 30, 2026 -- AC Immune SA (NASDAQ: ACIU), a clinical-stage biopharmaceutical company pioneering precision therapeutics for neurodegenerative diseases, today announced it dosed the first patients in Cohort AD4 in the ongoing Phase 1b/2 ABATE trial. As a result, AC Immune will receive a $12 million milestone payment from Takeda under the partners’ exclusive, worldwide option and license agreement for AC Immune’s active immunotherapies targeting toxic forms of amyloid beta (Abeta), including ACI-24 for the treatment of Alzheimer’s disease (AD).
ABATE is assessing ACI-24 in subjects with prodromal AD and in adults with Down syndrome (DS). AD4 includes subjects with prodromal AD.
Dr. Andrea Pfeifer, CEO of AC Immune SA, said: “This milestone underscores the progress in our Phase 1b/2 ABATE trial of ACI-24. AD4 will build on the encouraging early safety and immunogenicity data to date. It allows further evaluation of the potential of ACI-24 and, more broadly, our precision prevention approach to neurodegenerative diseases, which encompasses a pipeline of active immunotherapies and intracellular-targeted small-molecule therapeutics to intervene at the earliest stages of disease.”
ACI-24 is an anti-Abeta active immunotherapy candidate designed to induce a robust antibody response against the toxic forms of Abeta believed to drive plaque formation and AD progression. By inducing plaque clearance and efficiently inhibiting plaque formation in the brain, ACI-24 has the potential to delay or slow AD progression.
ACI-24 is being investigated in the ongoing ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial to assess its safety, tolerability, immunogenicity and pharmacodynamic effects. Data so far show that ACI-24 is generally safe and well tolerated, and that it has generated anti-Abeta antibody responses at all tested doses.
Cohorts AD1, AD2 and AD3 enrolled a total of 74 patients who received ACI-24 at escalating dose levels. The 12-month data readouts from Cohorts AD1, AD2 and AD3 are expected later in Q2 2026. Cohort AD4 will include an initial group of 36 patients treated for 12 months, with follow-up of 6 months, significantly expanding the safety and biomarker efficacy data set. A subsequent expansion of the AD4 cohort could potentially see the total number of subjects reach approximately 112 patients.
| PRESS RELEASE |
AC Immune is responsible for conducting the ABATE trial. Following the potential option exercise, Takeda would conduct and fund all further clinical development and be responsible for all global regulatory activities as well as worldwide commercialization.
Under the terms of the agreement with Takeda, AC Immune received an upfront payment of $100 million and is eligible to receive an option exercise fee and additional potential development, commercial and sales-based milestones of up to approximately $2.1 billion, if all related milestones are achieved over the course of the agreement. Upon commercialization, AC Immune will be entitled to receive tiered double-digit royalties on worldwide net sales.
About ACI-24
This product is AC Immune’s anti-Abeta active immunotherapy candidate. The ABATE randomized, double-blind, placebo-controlled Phase 1b/2 trial of ACI-24 for treatment of Alzheimer’s disease (AD) continues fully blinded (NCT05462106). Enrolled patients are required to have a diagnosis of prodromal AD: MCI due to AD according to the National Institute on Aging Alzheimer’s Association (NIA-AA) criteria, and a PET scan at screening must be consistent with the presence of amyloid pathology. Patients will be randomized to one of several doses of ACI-24 or placebo. Following multiple data safety monitoring board (DSMB) reviews, no safety concerns have been raised to date, consistent with previous results. Very encouraging immunogenicity has been shown with clear evidence of anti-Abeta antibody responses against toxic Abeta species observed in the blinded data.
About AC Immune SA
AC Immune SA is a clinical-stage biopharmaceutical company and a global leader in precision prevention for neurodegenerative diseases, including Alzheimer’s disease, Parkinson’s disease, and NeuroOrphan indications driven by misfolded proteins. The Company’s two clinically validated technology platforms, SupraAntigen® and Morphomer®, fuel its pipeline of first- and best-in-class assets, which currently features a range of therapeutic and diagnostic programs, including candidates in Phase 2 and Phase 3 development. AC Immune has a strong track record of securing strategic partnerships with leading global pharmaceutical companies, resulting in substantial non-dilutive funding to advance its proprietary programs and >$4.5 billion in potential milestone payments plus royalties.
SupraAntigen® is a registered trademark of AC Immune SA in the following territories: AU, EU, CH, GB, JP, RU, SG and USA. Morphomer® is a registered trademark of AC Immune SA in CA, CN, CH, EU, GB, JP, KR, NO, RU and SG.
The information on our website and any other websites referenced herein is expressly not incorporated by reference into, and does not constitute a part of, this press release.
For further information, please contact:
| SVP, Investor
Relations & Corporate Communications Gary Waanders, Ph.D., MBA AC Immune Phone: +41 21 345 91 91 Email: gary.waanders@acimmune.com |
|
| International Media Chris Maggos Cohesion Bureau Phone: +41 79 367 6254 Email: chris.maggos@cohesionbureau.com |
| PRESS RELEASE |
Forward looking statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Forward-looking statements are statements other than historical fact and may include statements that address future operating, financial or business performance or AC Immune’s strategies or expectations. In some cases, you can identify these statements by forward-looking words such as “may,” “might,” “will,” “should,” “expects,” “plans,” “anticipates,” “believes,” “estimates,” “predicts,” “projects,” “potential,” “outlook” or “continue,” and other comparable terminology. Forward-looking statements are based on management’s current expectations and beliefs and involve significant risks and uncertainties that could cause actual results, developments and business decisions to differ materially from those contemplated by these statements. These risks and uncertainties include those described under the captions “Item 3. Key Information – Risk Factors” and “Item 5. Operating and Financial Review and Prospects” in AC Immune’s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission. Forward-looking statements speak only as of the date they are made, and AC Immune does not undertake any obligation to update them in light of new information, future developments or otherwise, except as may be required under applicable law. All forward-looking statements are qualified in their entirety by this cautionary statement.